Bank of America raises Sino Biopharm stock target to HKD 7.40

Published on 10/20/2026 at 22:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 10.60 percent to RMB 19.44 billion. Sino Biopharm stock costs EUR 0.61 on October 20, 2026 at Lang & Schwarz.

Analyst target and interim figures

Bank of America Securities raised its Sino Biopharm target from HKD 7.30 to HKD 7.40 on October 2, 2026.
First-half 2026 revenue increased 10.60 percent to RMB 19.44 billion.
Sino Biopharm stock costs EUR 0.61 at Lang & Schwarz on October 20, 2026 at 10:20 p.m. CEST.

Sino Biopharm, KYG8167W1380, Illustration mit AI erstellt.

Sino Biopharm stock has a higher analyst target after Bank of America Securities raised its valuation from HKD 7.30 to HKD 7.40 on October 2, 2026. The new target stood 37.04 percent above the HKD 5.40 last price on HKEX on October 20, 2026 at 4:08 p.m. HKT. The stock was at EUR 0.61 at Lang & Schwarz on October 20, 2026 at 10:20 p.m. CEST.

Target rises on biosimilar deal

According to AASTOCKS, Bank of America Securities reiterated a Buy rating while lifting the target to HKD 7.40. The report linked the valuation change to Sino Biopharm's biosimilar collaboration with STADA, which covers European commercialization rights for pembrolizumab biosimilar TQB3570 and includes up to EUR 53.00 million in development, regulatory and sales milestones.

Revenue reaches RMB 19.44 billion

Sino Biopharm's first-half 2026 revenue increased 10.60 percent from RMB 17.57 billion a year earlier to RMB 19.44 billion. FinancialFilings reported that underlying profit rose 8.10 percent to RMB 3.34 billion, while innovative-drug and out-licensing revenue climbed 44.30 percent to RMB 8.79 billion.

Price position and valuation

On October 20, 2026, Sino Biopharm's HKEX quote stood at HKD 5.40, down from HKD 5.25 in the prior quote field and below the 52-week high of HKD 7.56. The 52-week low was HKD 4.19, while market capitalization was HKD 96.1 billion and the price-to-earnings ratio was 34.73.

Valuation and next reporting date

The company's interim report declared an HKD 0.07 dividend per share for the six months ended June 30, 2026. The next earnings report is scheduled for April 1, 2027, according to TradingView.

Comparison with peers

Sino Biopharm: HKD 5.40, P/E 34.73, market capitalization HKD 96.1 billion.
Jiangsu Hengrui Medicine: CNY 47.45, up 2.97 percent, P/E 40.56, market capitalization CNY 302.7 billion.
CSPC Pharmaceutical Group: HKD 8.92, up 0.45 percent, P/E 11.67, market capitalization HKD 101.7 billion.

Stock stays below analyst target

The higher target places the emphasis on Sino Biopharm's ability to convert licensing activity into recurring innovative-drug revenue. The first-half figures show that this business already represented 45.20 percent of total revenue, up from 34.70 percent a year earlier.

The further course of trading is shown by the continuously updated real-time quote of Sino Biopharm stock.